Browse evidence-based analysis of health-related claims and assertions
Prostate cancer is the #1 cancer diagnosis and killer for Black men in the U.S. and Caribbean — more than any other cancer.
Descriptive
Even though fewer African men are diagnosed with prostate cancer, a much higher percentage of them die from it — meaning many cases are never caught in time.
We don’t yet know if screening men with BRCA mutations for prostate cancer actually saves lives or improves how they feel long-term.
Countries that spend more on healthcare and have more doctors tend to find more small, early prostate cancers — probably because they do more testing.
Correlational
Standard PSA tests or MRI scans aren’t good enough on their own to find dangerous prostate cancers in men with BRCA mutations—they need better ways to tell who’s really at risk.
When Black men in Africa are diagnosed with prostate cancer, their tumors are usually much bigger and more dangerous-looking under the microscope than when Black men in the U.S. are diagnosed.
Having a BRCA1 mutation raises prostate cancer risk, but not as much as having a BRCA2 mutation.
Black men in the U.S. get diagnosed with prostate cancer more often than Black men in Africa or the Caribbean, but that might be because doctors in the U.S. test for it more.
When men with BRCA2 mutations get prostate cancer, it’s often more aggressive and shows up earlier in life than in men without the mutation.
Men who inherit a faulty BRCA2 gene are 2 to 4 times more likely to get prostate cancer than men without it.
If people think only men with peeing problems get prostate cancer, then healthy-seeming men won’t get checked—and that’s dangerous because cancer can be silent.
Most people think if you don’t have trouble peeing, you don’t have prostate cancer—but that’s wrong; most early cancers cause no symptoms at all.
A normal PSA reading can be misleading if your prostate is small—doctors do better at spotting cancer by comparing PSA to prostate size.
Quantitative
Prostate cancer grows on the outside of the prostate, while urinary problems come from swelling in the middle—so one doesn’t cause the other.
Mechanistic
Men who wait until they have trouble peeing to get checked for prostate cancer are much more likely to find out their cancer is already spread, compared to men who get tested even if they feel fine.
Most early prostate cancers don’t cause any urinary problems—so if a man has trouble peeing, it’s probably not cancer, and if he has no symptoms at all, he could still have cancer.
After removing the tumors, the man’s urinary problems didn’t get worse, and a year later, the tumors hadn’t come back.
The tumors in this man’s pelvic organs looked like classic benign nerve tumors under the microscope — they had two distinct tissue patterns, stained positive for S100, and showed no signs of cancer.
Even though this man’s PSA level was normal, an MRI scan showed a spot in his prostate that looked like cancer — but it turned out to be a harmless nerve tumor.
Doctors removed a growth near the bladder and took tissue samples from the prostate and seminal vesicle using minimally invasive techniques; the patient recovered well and his urinary symptoms didn’t get worse after one year.
An older man with a known nerve disorder had three unusual growths in his pelvic area that doctors found to be harmless nerve tumors after testing tissue samples.
Germline mutations in BRCA1 and BRCA2 genes confer a significantly elevated risk of developing prostate cancer in men, independent of family history of prostate cancer.
Assertion
Ethnicity is a significant biological determinant of prostate cancer risk, with men of African descent exhibiting approximately double the incidence and earlier age of onset compared to men of European descent.
Hematuria, whether gross or microscopic, is a pathological indicator requiring clinical evaluation due to its association with urological malignancies, including prostate and bladder cancer.